Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENCALL phase 2 study of Senl_B19 autologous T-cell injection in relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia
CTR20250078Phase 2Active
- Sponsor
- Senlang Bio
- Start
- Jan 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of SENL-B19 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Senlang Bio. Started Jan 2025; status: active.
02
Drugs
SENL-B19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on CTR20250078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250078.